<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04464694</url>
  </required_header>
  <id_info>
    <org_study_id>XH-20-011</org_study_id>
    <nct_id>NCT04464694</nct_id>
  </id_info>
  <brief_title>Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema</brief_title>
  <official_title>Prospective, Single-blind, Randomised, Controlled, Multi-centre Study to Evaluate the Benefit of Ranibizumab as an Adjunctive Therapy to Vitrectomy for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate ranibizumab's benefit on prevention of early postoperative vitreous
      haemorrhage in PDR-DME patients receiving vitrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective: To investigate ranibizumab's benefit on prevention of early postoperative
      vitreous haemorrhage in PDR-DME patients receiving vitrectomy.

      Secondary Objective:To investigate ranibizumab's additional benefit on visual improvement,
      facilitation of surgery and postoperative outcomes in PDR-DME patients receiving vitrectomy.

      Study design: This study is a prospective, randomized, single-blinded, blank-controlled,
      multi-center clinical trial that requires vitrectomy for PDR-DME patients.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early postoperative vitreous haemorrhage</measure>
    <time_frame>From day 1 to week 4 after the vitrectomy</time_frame>
    <description>To compare the incidence of the early postoperative vitreous haemorrhage between two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Best-corrected visual acuity (BCVA) at Month 3</measure>
    <time_frame>Month 3 after vitrectomy</time_frame>
    <description>To compare the changes from baseline BCVA to mean BCVA at month 3 between two arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Best-corrected visual acuity (BCVA) at Month 6</measure>
    <time_frame>Month 6 after vitrectomy</time_frame>
    <description>To compare the changes from baseline BCVA to mean BCVA at month 6 between two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Proliferative Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal injection of ranibizumab (0.5 mg) 3~7 days before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham injection 3~7 days before vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Patients will receive single intravitreal injection of Ranibizumab 0.5 mg 3~7 days before vitrectomy.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Patients will receive single sham injection 3~7 days before vitrectomy.</description>
    <arm_group_label>Sham injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pars plana vitrectomy</intervention_name>
    <description>Surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_label>Sham injection</arm_group_label>
    <other_name>Vitrectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ageâ‰¥18 years old;

          2. Type I or II diabetes mellitus, clinically diagnosed as diabetic macular edema

          3. Diagnosed as proliferative diabetic retinopathy and pas plana vitrectomy (PPV) is
             required to undergo due to non-absorbent vitreous hemorrhage (VH), fibrovascular
             proliferation with vitreoretinal adhesions or tractional retinal detachment (TRD); or
             active severe proliferative retinopathy not responding to previous panretinal laser
             photocoagulation; as well as other indications of PPV at the investigator's discretion

          4. Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

        Exclusion Criteria:

          1. Pregnancy or lactation;

          2. History of stroke, peripheral vascular disease, angina or myocardial infarction within
             six months

          3. Intraocular treatment with corticosteroids, anti-vascular endothelium growth factor or
             intraocular surgery within 45 days preceding baseline;

          4. Clinically confirmed intraocular pressure (IOP) &gt;=21 mmHg, uncontrolled glaucoma or
             iris neovascularization in either eye
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peiquan Zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peiquan Zhao</last_name>
    <phone>13311620396</phone>
    <email>Zhaopeiquan@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ningbo Eye Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315012</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Quanyong Yi</last_name>
      <phone>13586543802</phone>
      <email>1067572232@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eye &amp; Ent Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>2000831</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Huang</last_name>
      <phone>13818902665</phone>
      <email>xinhuang66@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>2000892</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peiquan Zhao</last_name>
      <phone>+8613311620396</phone>
      <email>zhaopeiquan@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lo WR, Kim SJ, Aaberg TM Sr, Bergstrom C, Srivastava SK, Yan J, Martin DF, Hubbard GB 3rd. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. 2009 Jul-Aug;29(7):926-31. doi: 10.1097/IAE.0b013e3181a8eb88.</citation>
    <PMID>19584650</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhao LQ, Zhu H, Zhao PQ, Hu YQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011 Sep;95(9):1216-22. doi: 10.1136/bjo.2010.189514. Epub 2011 Jan 27. Review.</citation>
    <PMID>21278146</PMID>
  </results_reference>
  <results_reference>
    <citation>Comyn O, Wickham L, Charteris DG, Sullivan PM, Ezra E, Gregor Z, Aylward GW, da Cruz L, Fabinyi D, Peto T, Restori M, Xing W, Bunce C, Hykin PG, Bainbridge JW. Ranibizumab pretreatment in diabetic vitrectomy: a pilot randomised controlled trial (the RaDiVit study). Eye (Lond). 2017 Sep;31(9):1253-1258. doi: 10.1038/eye.2017.75. Epub 2017 May 12.</citation>
    <PMID>28498374</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 5, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PDR</keyword>
  <keyword>DME</keyword>
  <keyword>ranibizumab</keyword>
  <keyword>vitrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

